(0.74%) 5 120.00 points
(0.21%) 38 367 points
(1.00%) 17 744 points
(0.28%) $83.80
(-3.54%) $1.580
(0.79%) $2 360.90
(1.36%) $27.73
(0.55%) $925.60
(-0.10%) $0.931
(0.06%) $10.96
(-0.16%) $0.798
(0.08%) $92.25
Live Chart Being Loaded With Signals
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases...
Stats | |
---|---|
Today's Volume | 6 663.00 |
Average Volume | 37 849.00 |
Market Cap | 126.29M |
EPS | €0 ( 2024-03-27 ) |
Next earnings date | ( €0 ) 2024-05-14 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -5.71 |
ATR14 | €0.00400 (0.32%) |
Transgene SA Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Transgene SA Financials
Annual | 2023 |
Revenue: | €1.18M |
Gross Profit: | €-28.40M (-2 398.99 %) |
EPS: | €-0.220 |
FY | 2023 |
Revenue: | €1.18M |
Gross Profit: | €-28.40M (-2 398.99 %) |
EPS: | €-0.220 |
FY | 2022 |
Revenue: | €3.13M |
Gross Profit: | €-29.04M (-929.05 %) |
EPS: | €-0.330 |
FY | 2021 |
Revenue: | €9.99M |
Gross Profit: | €0.00 (0.00 %) |
EPS: | €-0.233 |
Financial Reports:
No articles found.
Transgene SA
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators